07:00 EDT Novavax (NVAX) jumps 15% to $7.73 after FDA approves COVID vaccine
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax’s Strategic Positioning and Regulatory Milestones Drive Buy Rating
- FDA approves Novavax COVID-19 vaccine with restrictions
- Novavax COVID-19 vaccine approved by FDA with restrictions, AP News says
- HHS to drop recommendations for routine COVID shots for kids, WSJ reports
- FDA head says vaccine framework being prepared